Emerging role of NLRP3 inflammasome as a therapeutic target in cardiovascular and infectious diseases

Na Li,
Associate Professor, Department of Medicine, Baylor College of Medicine, Houston, TX, The United States of America

Targeting the NLRP3 inflammasome for the treatment of inflammatory diseases
Dr Rebecca Coll
Lecturer in Immunobiology, Queen’s University Belfast, Belfast, United Kingdom

CaMKII signaling and NLRP3 inflammasome activation in cardiomyocyte mediated inflammation
Professor Joan Heller Brown
Professor and Chair of the Department of Pharmacology, UC San Diego, School of Medicine, United States of America

Oral communication speaker - to be confirmed in 2023.

Pathological role of NLRP3 inflammasome in the development of atrial fibrillation
Dr Marcel Tekook
Department of Pharmacology, University of Duisburg – Essen Germany, Essen, Germany

Inflammasome activation and COVID-19 patients
Stefano Toldo Associate Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Virginia, School of Medicine, Molecular Research Building 5 (MR5), Charlottesville, VA, America